Eribulin in non-small cell lung cancer: challenges and potential strategies.

about

Eribulin in non-small cell lung cancer: challenges and potential strategies.

Item

http://www.wikidata.org/entity/Q39120142

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Eribulin in non-small cell lung cancer: challenges and potential strategies.

@en

Eribulin in non-small cell lung cancer: challenges and potential strategies.

@nl

type

Item

label

Eribulin in non-small cell lung cancer: challenges and potential strategies.

@en

Eribulin in non-small cell lung cancer: challenges and potential strategies.

@nl

prefLabel

Eribulin in non-small cell lung cancer: challenges and potential strategies.

@en

Eribulin in non-small cell lung cancer: challenges and potential strategies.

@nl

P1476

Eribulin in non-small cell lung cancer: challenges and potential strategies

@en

P2093

Sanjay Goel

http://www.w3.org/2001/XMLSchema#string

Umang Shah

http://www.w3.org/2001/XMLSchema#string

P2860

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

Eribulin in Cancer Treatment

Termination of Protofilament Elongation by Eribulin Induces Lattice Defects that Promote Microtubule Catastrophes

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Effects of eribulin on microtubule binding and dynamic instability are strengthened in the absence of the βIII tubulin isotype

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions

Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells

P304

495-508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1292250

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Umang Swami

P577

2017-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28161993

http://www.w3.org/2001/XMLSchema#string